Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472297 | 0.96 | PDE4B (0.54) | PDE4BPDE7APDE3BPDE3A | |
| SCHEMBL1471906 | 0.91 | PDE4B (0.52) | PDE4BADORA1PDE7APDE3BPDE3A | |
| SCHEMBL1472534 | 0.90 | PDE4B (0.55) | PDE4BPDE7APDE3BPDE3AMEN1 | |
| SCHEMBL1472344 | 0.86 | PDE4B (0.47) | PDE4BADORA1PDE7APDE3BPDE3A | |
| SCHEMBL1474527 | 0.83 | PDE4B (0.48) | PDE4BADORA1PDE7APDE3BPDE3A | |
| SCHEMBL1471274 | 0.83 | PDE4B (0.51) | PDE4BPDE7APDE3BPDE3A | |
| SCHEMBL583329 | 0.82 | PDE4B (0.52) | PDE4BPDE7A | |
| SCHEMBL1944087 | 0.82 | PDE4B (0.54) | PDE4BPDE7APDE3BPDE3A | |
| SCHEMBL1471472 | 0.81 | PDE4B (0.49) | PDE4BADORA1PDE7APDE3BPDE3A | |
| SCHEMBL1944193 | 0.81 | PDE4B (0.44) | PDE4BPDE7APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | claimed |
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | claimed |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-10 | — | — | US | claimed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4B, PDE3A | PDE4B 2/4885ADORA1 792/4885PDE7A 11/4885 |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | PDE4B 3/4885ADORA1 970/4885PDE7A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.